Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis
The aims of this study were to assess the prevalence of, and risk factors for, Chlamydia trachomatis in attendees recruited prospectively from October 2018 to January 2019 at the only sexually transmitted infections clinic in Iceland (in Reykjavík), and to evaluate the cobas 4800 CT/NG Test and Apti...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Society for Publication of Acta Dermato-Venereologica
2021-02-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3762
|
id |
doaj-15df8e1488994a6a8dc20f12ee30a1be |
---|---|
record_format |
Article |
spelling |
doaj-15df8e1488994a6a8dc20f12ee30a1be2021-02-11T09:44:20ZengSociety for Publication of Acta Dermato-VenereologicaActa Dermato-Venereologica0001-55551651-20572021-02-011012adv0039310.2340/00015555-37626007Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for DiagnosisIngibjorg Hilmarsdóttir0Eva Mjöll ArnardóttirElísabet Reykdal JóhannesdóttirDaniel GolparianMagnus Unemo Department of Microbiology, Landspítali - The University Hospital of Iceland, 101 Reykjavik, Iceland. E-mail: ingibjh@landspitali.is. The aims of this study were to assess the prevalence of, and risk factors for, Chlamydia trachomatis in attendees recruited prospectively from October 2018 to January 2019 at the only sexually transmitted infections clinic in Iceland (in Reykjavík), and to evaluate the cobas 4800 CT/NG Test and Aptima Combo 2 Assay for C. trachomatis detection in male urine and female vaginal swabs. Prevalence of C. trachomatis was 15.8% among 487 women and 13.6% among 491 men (no Neisseria gonorrhoeae positive patients were found). C. trachomatis detection was independently and positively associated with being tested for contact tracing, 18–24 years of age, and reporting ≥ 6 sexual partners within 12 months. Reporting sex with non-residents of Iceland was associated with a lower risk of C. trachomatis infection. Both assays had a high sensitivity in detection of C. trachomatis (Aptima Combo 2: 100%; cobas 4800 CT/NG: 95.1%) and high specificity (100% and 99.6%, respectively). The high local prevalence of C. trachomatis and increased acquisition risk following sex with residents are of public health concern. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3762 chlamydia trachomatis neisseria gonorrhoeae prevalence risk factor nucleic acid amplification iceland sexually transmitted disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ingibjorg Hilmarsdóttir Eva Mjöll Arnardóttir Elísabet Reykdal Jóhannesdóttir Daniel Golparian Magnus Unemo |
spellingShingle |
Ingibjorg Hilmarsdóttir Eva Mjöll Arnardóttir Elísabet Reykdal Jóhannesdóttir Daniel Golparian Magnus Unemo Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis Acta Dermato-Venereologica chlamydia trachomatis neisseria gonorrhoeae prevalence risk factor nucleic acid amplification iceland sexually transmitted disease |
author_facet |
Ingibjorg Hilmarsdóttir Eva Mjöll Arnardóttir Elísabet Reykdal Jóhannesdóttir Daniel Golparian Magnus Unemo |
author_sort |
Ingibjorg Hilmarsdóttir |
title |
Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis |
title_short |
Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis |
title_full |
Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis |
title_fullStr |
Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis |
title_full_unstemmed |
Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis |
title_sort |
chlamydia trachomatis in iceland: prevalence, clinico-epidemiological features and comparison of cobas 480 ct/ng and aptima combo 2 (ct/ng) for diagnosis |
publisher |
Society for Publication of Acta Dermato-Venereologica |
series |
Acta Dermato-Venereologica |
issn |
0001-5555 1651-2057 |
publishDate |
2021-02-01 |
description |
The aims of this study were to assess the prevalence of, and risk factors for, Chlamydia trachomatis in attendees recruited prospectively from October 2018 to January 2019 at the only sexually transmitted infections clinic in Iceland (in Reykjavík), and to evaluate the cobas 4800 CT/NG Test and Aptima Combo 2 Assay for C. trachomatis detection in male urine and female vaginal swabs. Prevalence of C. trachomatis was 15.8% among 487 women and 13.6% among 491 men (no Neisseria gonorrhoeae positive patients were found). C. trachomatis detection was independently and positively associated with being tested for contact tracing, 18–24 years of age, and reporting ≥ 6 sexual partners within 12 months. Reporting sex with non-residents of Iceland was associated with a lower risk of C. trachomatis infection. Both assays had a high sensitivity in detection of C. trachomatis (Aptima Combo 2: 100%; cobas 4800 CT/NG: 95.1%) and high specificity (100% and 99.6%, respectively). The high local prevalence of C. trachomatis and increased acquisition risk following sex with residents are of public health concern. |
topic |
chlamydia trachomatis neisseria gonorrhoeae prevalence risk factor nucleic acid amplification iceland sexually transmitted disease |
url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3762
|
work_keys_str_mv |
AT ingibjorghilmarsdottir chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis AT evamjollarnardottir chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis AT elisabetreykdaljohannesdottir chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis AT danielgolparian chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis AT magnusunemo chlamydiatrachomatisinicelandprevalenceclinicoepidemiologicalfeaturesandcomparisonofcobas480ctngandaptimacombo2ctngfordiagnosis |
_version_ |
1724274357738405888 |